By Fineline Cube 
China-based CanSino Biologics Inc., (HKG: 6185) announced that it and its subsidiary CanSino (Shanghai) Biotechnology have received a clinical-trial permit from the National Medical Products Administration (NMPA). This approval is for their recombinant trivalent polio vaccine produced in Sf-RVN cells, paving the way for a study aimed at preventing infection by poliovirus types I, II, and III.
Vaccine Innovation
The candidate vaccine is classified as a Category 1.2 prophylactic biologic. It is built with protein-structure design and virus-like particle (VLP) assembly technology. Notably, it contains no viral genetic material and is manufactured and tested without the use of live virus. This profile is expected to provide strong safety and immunogenicity benefits.
Global Eradication Efforts
The World Health Organization (WHO) has identified non-infectious VLP-based polio vaccines as the preferred platform for the final phase of global eradication efforts. This recognition underscores the potential impact of CanSinoBio’s vaccine in the global fight against polio.
Clinical Trial Progress
Separately, the product is already in a Phase I/II trial in Indonesia, where the first participant has been dosed, as previously announced. This highlights the international collaboration and progress in advancing the vaccine’s development.-Fineline Info & Tech